DOGMATIL 200MG TAB

Indications

Approved Uses

Schizophrenia and other acute/chronic psychotic disorders (antipsychotic indication).

Side Effects

Common Side Effects

Hyperprolactinemia (amenorrhea, galactorrhea, gynecomastia, sexual dysfunction), extrapyramidal symptoms (e.g., akathisia, tremor, rigidity), sedation/drowsiness or insomnia, weight gain, constipation, dry mouth; rash can occur.

Side Effect Frequency

Hyperprolactinemia and related endocrine effects (e.g., galactorrhea, amenorrhea, gynecomastia/sexual dysfunction) and extrapyramidal symptoms (e.g., akathisia, dystonia/parkinsonism) are common; sedation/drowsiness, insomnia, constipation and weight gain are common; orthostatic hypotension and QT prolongation/ventricular arrhythmias are uncommon to rare; neuroleptic malignant syndrome, tardive dyskinesia, seizures, and blood dyscrasias (e.g., agranulocytosis) are rare.

Drug Interactions

Drug Interactions

Major interactions: levodopa/dopamine agonists (reciprocal antagonism); alcohol/CNS depressants (additive sedation); antihypertensives (additive hypotension); QT‑prolonging drugs (additive torsades risk); lithium (increased neurotoxicity/EPS risk); antacids/sucralfate (reduced sulpiride absorption-separate dosing).

Alcohol Interaction

Avoid

Special Populations

Breastfeeding

Avoid in mothers with history of major depression; use with caution otherwise; increases prolactin and may cause galactorrhea

Storage & Patient Advice

Overdose

Expected overdose effects: sedation, hypotension, extrapyramidal symptoms, agitation/confusion, and potential QT prolongation/ventricular arrhythmias (including torsades) and coma; management is supportive (airway/ventilation, IV fluids/vasopressors as needed), consider activated charcoal if early, and continuous ECG/cardiac monitoring-no specific antidote.

Pharmacology

Mechanism of Action

Dopamine D2 (and to a lesser extent D3) receptor antagonist; at low doses preferential presynaptic autoreceptor blockade may increase dopaminergic transmission, while higher doses block postsynaptic receptors producing antipsychotic effects.

Bioavailability

Approximately 25-35% (low oral bioavailability).

Metabolism

Minimal hepatic metabolism; predominantly eliminated unchanged via renal excretion (not significantly metabolized by CYP450).

Excretion

Primarily renal excretion as unchanged drug (majority in urine, commonly ~70-90%); minor fecal excretion.

Product Information

Composition per Dose

Each scored tablet: 200mg sulpiride

Generic Availability

Yes

Psych Class

Antipsychotic-Atypical

Controlled Substance

No

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.